Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 3 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

0
Player Avatar JohanHansen (75.47) Submitted: 3/16/2010 10:08:24 PM : Outperform Start Price: $7.42 ELN Score: +79.58

bvbb

Featured Broker Partners


Advertisement